Maven Securities LTD Acquires New Position in Unity Biotechnology, Inc. (NASDAQ:UBX)

Maven Securities LTD acquired a new stake in Unity Biotechnology, Inc. (NASDAQ:UBX – Get Rating) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 100,000 shares of the company’s stock, valued at approximately $40,000.

Several other institutional investors also recently made changes to their positions in UBX. Acadian Asset Management LLC grew its holdings in shares of Unity Biotechnology by 39.8% during the first quarter. Acadian Asset Management LLC now owns 389,893 shares of the company’s stock valued at $435,000 after purchasing an additional 111,097 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Unity Biotechnology by 5.6% during the second quarter. Renaissance Technologies LLC now owns 957,718 shares of the company’s stock valued at $540,000 after purchasing an additional 51,003 shares during the last quarter. Virtu Financial LLC grew its holdings in shares of Unity Biotechnology by 25.4% during the second quarter. Virtu Financial LLC now owns 62,640 shares of the company’s stock valued at $35,000 after purchasing an additional 12,681 shares during the last quarter. State Street Corp grew its holdings in shares of Unity Biotechnology by 21.0% during the second quarter. State Street Corp now owns 130,440 shares of the company’s stock valued at $74,000 after purchasing an additional 22,600 shares during the last quarter. Finally, ExodusPoint Capital Management LP acquired a new position in shares of Unity Biotechnology during the third quarter worth approximately $201,000.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on UBX. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Unity Biotechnology in a research report on Wednesday, February 15th. Mizuho reduced their price objective on Unity Biotechnology from $80.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday, November 16th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $34.50.

Unity Biotechnology Stock Performance

UBX opened at $4.17 on Wednesday. The company has a market capitalization of $59.17 million, a price-to-earnings ratio of -0.51 and a beta of 0.79. The company has a debt-to-equity ratio of 0.17, a current ratio of 6.12 and a quick ratio of 6.12. Unity Biotechnology, Inc. has a 1-year low of $2.09 and a 1-year high of $18.50. The business has a 50 day moving average price of $4.25 and a two-hundred day moving average price of $3.87.

About Unity Biotechnology

(Get Rating)

Unity Biotechnology, Inc operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.